Meda announces acquisition of global rights to erectile dysfunction product MUSE

Meda (STO:MEDAA) today announced the acquisition of global rights to MUSE (transurethral alprostadil), a well established product for the treatment of erectile dysfunction.

Meda has had the distribution rights to MUSE in Europe for many years. Meda will now take over global rights and all assets relating to the product. The largest market is the US where annual sales are approximately 15 MUSD.

The acquisition price is an upfront payment of 22 MUSD and a potential sales milestone payment of 1,5 MUSD based on future sales of MUSE. The transaction is subject to standard closing requirements. The transaction is expected to close within 60 days.

Source:

MEDA AB

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study uncovers sex differences in brain responses to low sexual desire